CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 11 enrolled
Drug / intervention
Autologous HIV-1 ApB DC Vaccinebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00510497
NCT00510497Phase 2Completed
CompareCT.gov

Phase I/II Evaluation of Therapeutic Immunization With Autologous Dendritic Cells Pulsed With Autologous, Inactivated HIV-1 Infected, Apoptotic Cells

Sharon Riddler·interventional·Posted Aug 2, 2007·Updated Nov 6, 2025

In Brief

A Phase 2 clinical trial evaluating Autologous HIV-1 ApB DC Vaccine for HIV Infections. Completed, enrolled 11 participants across 1 site.

Detailed Summary

This study aims to look at the safety and tolerability of immunization with dendritic cell vaccine prepared using the patient's own cells and virus. It also aims to explore the virologic efficacy of the vaccine as determined by a decrease in the viral load 12 weeks after analytic treatment interruption.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesUnited States
CollaboratorsNational Institute of Allergy and Infectious Diseases (NIAID)

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 2, 2007
Enrollment StartJul 1, 2007
Primary CompletionSep 1, 2012
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 18.9 years ago

Interventions

Autologous HIV-1 ApB DC Vaccinebiological

Autologous dendritic cells pulsed with autologous, inactivated HIV-1 infected, apoptotic cells given subcutaneously 3 times every other week plus a booster dose 2 weeks after start of treatment interruption